Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Expected to Post FY2026 Earnings of $4.10 Per Share

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a report issued on Monday, April 29th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of $4.10 per share for the year, up from their prior forecast of $3.86. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2027 earnings at $7.94 EPS and FY2028 earnings at $10.75 EPS.

A number of other analysts have also recently commented on ATNM. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Maxim Group boosted their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $25.72.

Actinium Pharmaceuticals Price Performance

Actinium Pharmaceuticals stock opened at $7.80 on Tuesday. The company has a market capitalization of $232.28 million, a PE ratio of -4.56 and a beta of 0.01. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals during the first quarter worth $78,000. Creative Financial Designs Inc. ADV boosted its stake in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares during the last quarter. Finally, Brandywine Global Investment Management LLC acquired a new position in Actinium Pharmaceuticals during the third quarter worth $1,033,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.